Streptococcal bacteriocins and the case for Streptococcus salivarius as model oral probiotics

Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest

Bibliography

• 1  Facklam R: What happened to the streptococci: overview of taxonomic and nomenclature changes. Clin. Microbiol. Rev.15,613–630 (2002).
  MedlineGoogle Scholar
• 2  Pasteur L, Joubert JF: Charbon et septicémie. C. R. Soc. Biol. Paris85,101–115 (1877).
  Google Scholar
• 3  Tagg JR, Bannister LV: “Fingerprinting” β-haemolytic streptococci by their production of and sensitivity to bacteriocine-like inhibitors. J. Med. Microbiol.12,397–411 (1979).▪▪ Original description of the deferred antagonism method, which has subsequently been used as the reference for the production (P)-typing of streptococcal bacteriocin-producing strains and is a useful first screen for novel bacteriocin producers.
  Medline CASGoogle Scholar
• 4  Tagg JR: Streptococcal bacteriocin-like inhibitory substances: some personal insights into the bacteriocin-like activities produced by streptococci good and bad. Probiotics Antimicro. Prot.1,60–66 (2009).
  Medline CASGoogle Scholar
• 5  Qi F, Chen P, Caufield PW: The group I strain of Streptococcus mutans, UA140, produces both the lantibiotic mutacin I and a nonlantibiotic bacteriocin, mutacin IV. Appl. Environ. Microbiol.67,15–21 (2001).
  Medline CASGoogle Scholar
• 6  Wirawan RE, Swanson KM, Kleffmann T, Jack RW, Tagg JR: Uberolysin: a novel cyclic bacteriocin produced by Streptococcus uberis. Microbiology153,1619–1630 (2007).▪ First report of a cyclic bacteriocin produced by a streptococcal species.
  Medline CASGoogle Scholar
• 7  Tagg JR, Dajani AS, Wannamaker LW: Bacteriocins of Gram-positive bacteria. Bacteriol. Rev.40,722–756 (1976).▪▪ Predicts the huge surge in interest in bacteriocins from Gram-positive bacteria and gives a useful overview of the characteristics of these bacteriocins.
  Medline CASGoogle Scholar
• 8  Jack RW, Tagg JR, Ray B: Bacteriocins of Gram-positive bacteria. Microbiol. Rev.59,171–200 (1995).▪ Describes advances in bacteriocin biology in the decades since the Tagg et al. review [7].
  Medline CASGoogle Scholar
• 9  Heng NCK, Wescombe PA, Burton JP, Jack RW, Tagg JR: The diversity of bacteriocins produced by Gram-positive bacteria. In: Bacteriocins – Ecology and Evolution. Riley MA, Chavan MA (Eds). Springer-Verlag, Berlin, Germany, 45–92 (2007).▪ Most recent review of the diversity of bacteriocins produced by Gram-positive bacteria. The division of all bacteriocins into the four distinct classes (outlined in this review) was first proposed here.
  Google Scholar
• 10  Wescombe PA, Heng NCK, Jack RW, Tagg JR: Bacteriocins associated with cytotoxicity for eukaryotic cells. In: Microbial Toxins Molecular and Cellular Biology. 399–448 (2005).
  Google Scholar
• 11  Jung G: Lantibiotics: a survey. In: Nisin and Novel Lantibiotics. Jung G, Sahl H-G (Eds). Escom Publishers, Leiden, The Netherlands, 1–34 (1991).
  Google Scholar
• 12  McAuliffe O, Ross RP, Hill C: Lantibiotics: structure, biosynthesis and mode of action. FEMS Microbiol. Rev.25,285–308 (2001).
  Medline CASGoogle Scholar
• 13  Chatterjee C, Paul M, Xie L, van der Donk WA: Biosynthesis and mode of action of lantibiotics. Chem. Rev.105,633–684 (2005).▪ Extremely comprehensive review of lantibiotics that covers nearly every aspect of these interesting and relevant molecules. Especially useful for researchers who want in-depth knowledge about the different groups of lantibiotics and their relatedness.
  Medline CASGoogle Scholar
• 14  Wescombe PA, Upton M, Dierksen KP et al.: Production of the lantibiotic salivaricin A and its variants by oral streptococci and use of a specific induction assay to detect their presence in human saliva. Appl. Environ. Microbiol.72,1459–1466 (2006).
  Medline CASGoogle Scholar
• 15  Simpson WJ, Ragland NL, Ronson CW, Tagg JR: A lantibiotic gene family widely distributed in Streptococcus salivarius and Streptococcus pyogenes. Dev. Biol. Stand.85,639–643 (1995).
  Medline CASGoogle Scholar
• 16  Phelps HA, Neely MN: SalY of the Streptococcus pyogenes lantibiotic locus is required for full virulence and intracellular survival in macrophages. Infect. Immun.75,4541–4551 (2007).▪▪ First description of a second function of a gene product from a lantibiotic locus. This paper describes the importance of the salivaricin A immunity protein for intracellular survival of Streptococcus pyogenes in phagocytes.
  Medline CASGoogle Scholar
• 17  Kizy AE, Neely MN: First Streptococcus pyogenes signature-tagged mutagenesis screen identifies novel virulence determinants. Infect. Immun.77,1854–1865 (2009).
  Medline CASGoogle Scholar
• 18  Tagg JR, Pybus V, Phillips LV, Fiddes TM: Application of inhibitor typing in a study of the transmission and retention in the human mouth of the bacterium Streptococcus salivarius. Arch. Oral Biol.28,911–915 (1983).
  Medline CASGoogle Scholar
• 19  Upton M, Tagg JR, Wescombe P, Jenkinson HF: Intra- and interspecies signaling between Streptococcus salivarius and Streptococcus pyogenes mediated by SalA and SalA1 lantibiotic peptides. J. Bacteriol.183,3931–3938 (2001).
  Medline CASGoogle Scholar
• 20  Dierksen KP, Moore CJ, Inglis M, Wescombe PA, Tagg JR: The effect of ingestion of milk supplemented with salivaricin A-producing Streptococcus salivarius on the bacteriocin-like inhibitory activity of streptococcal populations on the tongue. FEMS Microbiol. Ecol.59,584–591 (2007).
  Medline CASGoogle Scholar
• 21  Hyink O, Wescombe PA, Upton M, Ragland N, Burton JP, Tagg JR: Salivaricin A2 and the novel lantibiotic salivaricin B are encoded at adjacent loci on a 190-kilobase transmissible megaplasmid in the oral probiotic strain Streptococcus salivarius K12. Appl. Environ. Microbiol.73,1107–1113 (2007).
  Medline CASGoogle Scholar
• 22  Wescombe PA, Burton JP, Cadieux PA et al.: Megaplasmids encode differing combinations of lantibiotics in Streptococcus salivarius. Antonie Van Leeuwenhoek90,269–280 (2006).▪▪ First report of the existence of megaplasmids in streptococci.
  Medline CASGoogle Scholar
• 23  Wescombe PA: Characterisation of lantibiotics produced by Streptococcus salivarius and Streptococcus pyogenes. PhD thesis, Department of Microbiology and Immunology, University of Otago, Dunedin, New Zealand (2002).
  Google Scholar
• 24  Georgalaki MD, Van Den Berghe E, Kritikos D et al.: Macedocin, a food-grade lantibiotic produced by Streptococcus macedonicus ACA-DC 198. Appl. Environ. Microbiol.68,5891–5903 (2002).
  Medline CASGoogle Scholar
• 25  Hynes WL, Friend VL, Ferretti JJ: Duplication of the lantibiotic structural gene in M-type 49 group A streptococcus strains producing streptococcin A-M49. Appl. Environ. Microbiol.60,4207–4209 (1994).
  Medline CASGoogle Scholar
• 26  Papadelli M, Karsioti A, Anastasiou R, Georgalaki M, Tsakalidou E: Characterization of the gene cluster involved in the biosynthesis of macedocin, the lantibiotic produced by Streptococcus macedonicus. FEMS Microbiol. Lett.272,75–82 (2007).
  Medline CASGoogle Scholar
• 27  Karaya K, Shimizu T, Taketo A: New gene cluster for lantibiotic streptin possibly involved in streptolysin S formation. J. Biochem. (Tokyo)129,769–775 (2001).
  Medline CASGoogle Scholar
• 28  Wescombe PA, Tagg JR: Purification and characterization of streptin, a type A1 lantibiotic produced by Streptococcus pyogenes. Appl. Environ. Microbiol.69,2737–2747 (2003).
  MedlineGoogle Scholar
• 29  Hynes WL, Tagg JR: Bacteriocin-like activity of an M-type 25 group A streptococus. Proc. Univ. Otago Med. Sch.62,109–110 (1984).
  Google Scholar
• 30  Hynes WL, Tagg JR: Production of broad-spectrum bacteriocin-like activity by group A streptococci of particular M-types. Zentralbl. Bakteriol. Mikrobiol. Hyg. A259,155–164 (1985).
  Medline CASGoogle Scholar
• 31  Heng NC, Burtenshaw GA, Jack RW, Tagg JR: Ubericin A, a class IIa bacteriocin produced by Streptococcus uberis. Appl. Environ. Microbiol.73,7763–7766 (2007).
  Medline CASGoogle Scholar
• 32  Hale JD, Heng NC, Jack RW, Tagg JR: Identification of nlmTE, the locus encoding the ABC transport system required for export of nonlantibiotic mutacins in Streptococcus mutans. J. Bacteriol.187,5036–5039 (2005).
  Medline CASGoogle Scholar
• 33  Heng NC, Tagg JR, Tompkins GR: Competence-dependent bacteriocin production by Streptococcus gordonii DL1 (Challis). J. Bacteriol.189,1468–1472 (2007).
  Medline CASGoogle Scholar
• 34  Kreth J, Merritt J, Shi W, Qi F: Co-ordinated bacteriocin production and competence development: a possible mechanism for taking up DNA from neighbouring species. Mol. Microbiol.57,392–404 (2005).
  Medline CASGoogle Scholar
• 35  Kreth J, Merritt J, Shi W, Qi F: Competition and coexistence between Streptococcus mutans and Streptococcus sanguinis in the dental biofilm. J. Bacteriol.187,7193–7203 (2005).
  Medline CASGoogle Scholar
• 36  Heng NC, Tagg JR, Tompkins GR: Identification and characterization of the loci encoding the competence-associated alternative σ factor of Streptococcus gordonii. FEMS Microbiol. Lett.259,27–34 (2006).
  Medline CASGoogle Scholar
• 37  Hale JD, Ting YT, Jack RW, Tagg JR, Heng NC: Bacteriocin (mutacin) production by Streptococcus mutans genome sequence reference strain UA159: elucidation of the antimicrobial repertoire by genetic dissection. Appl. Environ. Microbiol.71,7613–7617 (2005).
  Medline CASGoogle Scholar
• 38  Perry JA, Jones MB, Peterson SN, Cvitkovitch DG, Levesque CM: Peptide alarmone signalling triggers an auto-active bacteriocin necessary for genetic competence. Mol. Microbiol.72(4),905–917 (2009).
  Medline CASGoogle Scholar
• 39  Akesson M, Dufour M, Sloan GL, Simmonds RS: Targeting of streptococci by zoocin A. FEMS Microbiol. Lett.270,155–161 (2007).
  Medline CASGoogle Scholar
• 40  Heng NC, Ragland NL, Swe PM et al.: Dysgalacticin: a novel, plasmid-encoded antimicrobial protein (bacteriocin) produced by Streptococcus dysgalactiae subsp. equisimilis. Microbiology152,1991–2001 (2006).
  Medline CASGoogle Scholar
• 41  Heng NC, Burtenshaw GA, Jack RW, Tagg JR: Sequence analysis of pDN571, a plasmid encoding novel bacteriocin production in M-type 57 Streptococcus pyogenes. Plasmid52,225–229 (2004).
  Medline CASGoogle Scholar
• 42  Beukes M, Hastings JW: Self-protection against cell wall hydrolysis in Streptococcus milleri NMSCC 061 and analysis of the millericin B operon. Appl. Environ. Microbiol.67,3888–3896 (2001).
  Medline CASGoogle Scholar
• 43  Simmonds RS, Naidoo J, Jones CL, Tagg JR: The streptococcal bacteriocin-like inhibitory substance, zoocin A, reduces the proportion of Streptococcus mutans in an artificial plaque. Microb. Ecol. Health Dis.8,281–292 (1995).
  Google Scholar
• 44  Heng NCK, Swe PM, Ting YT et al.: The large antimicrobial proteins (bacteriocins) of streptococci. Int. Congr. Ser.1289,351–354 (2006).
  CASGoogle Scholar
• 45  Swe PM, Cook GM, Tagg JR, Jack RW: Mode of action of dysgalacticin: a large heat-labile bacteriocin. J. Antimicrob. Chemother.63,679–686 (2009).
  Medline CASGoogle Scholar
• 46  Maqueda M, Galvez A, Bueno MM et al.: Peptide AS-48: prototype of a new class of cyclic bacteriocins. Curr. Protein Pept. Sci.5,399–416 (2004).
  Medline CASGoogle Scholar
• 47  Oe Y, Soejima H, Nakayama H et al.: Significant association between score of periodontal disease and coronary artery disease. Heart Vessels24,103–107 (2009).
  MedlineGoogle Scholar
• 48  Hillman JD, Mo J, McDonell E, Cvitkovitch D, Hillman CH: Modification of an effector strain for replacement therapy of dental caries to enable clinical safety trials. J. Appl. Microbiol.102,1209–1219 (2007).▪▪ Describes proposed use of a genetically modified member of the oral microbiota as a probiotic.
  Medline CASGoogle Scholar
• 49  Smith L, Hillman J: Therapeutic potential of type A (I) lantibiotics, a group of cationic peptide antibiotics. Curr. Opin. Microbiol.11,401–408 (2008).
  Medline CASGoogle Scholar
• 50  Smith L, Hasper H, Breukink E et al.: Elucidation of the antimicrobial mechanism of mutacin 1140. Biochemistry47,3308–3314 (2008).
  Medline CASGoogle Scholar
• 51  Ghobrial OG, Derendorf H, Hillman JD: Development and validation of a LC-MS quantification method for the lantibiotic MU1140 in rat plasma. J. Pharm. Biomed. Anal.49,970–975 (2009).
  Medline CASGoogle Scholar
• 52  Ghobrial OG, Derendorf H, Hillman JD: Pharmacodynamic activity of the lantibiotic MU1140. Int. J. Antimicrob. Agents33,70–74 (2009).
  Medline CASGoogle Scholar
• 53  Sanders E: Bacterial Interference. I. Its occurrence among the respiratory tract flora and characterisation of inhibition of group A streptococci by viridans streptococci. J. Infect. Dis.120,698–707 (1969).▪▪ Early important observation of potential interference with group A streptococcal establishment by commensal streptococci.
  Medline CASGoogle Scholar
• 54  Crowe CC, Sanders WE, Longley S: Bacterial interference. II. Role of the normal throat flora in prevention of colonization by group A Streptococcus. J. Infect. Dis.128,527–532 (1973).
  Medline CASGoogle Scholar
• 55  Bochkov IA: Nasopharyngeal microorganisms – antagonists of meningococci. Zh. Mikrobiol. Epidemiol. Immunobiol.81–86 (1975).
  MedlineGoogle Scholar
• 56  Sanders CC, Sanders WE, Harrowe DJ: Bacterial interference: effects of oral antibiotics on the normal throat flora and its ability to interfere with group A streptococci. Infect. Immun.13,808–812 (1976).
  Medline CASGoogle Scholar
• 57  Bill NJ, Washington JA: Bacterial interference by Streptococcus salivarius. Am. J. Clin. Pathol.64,116–120 (1975).
  Medline CASGoogle Scholar
• 58  Grahn E, Holm SE: Bacterial interference in the throat flora during a streptococcal tonsillitis outbreak in an apartment house area. Zentralbl. Bakteriol. Mikrobiol. Hyg. A256,72–79 (1983).
  Medline CASGoogle Scholar
• 59  Fujimori I, Nozawa I, Kikushima K, Goto R, Hisamatatsu K, Murakami Y: Interaction between oral α-streptococci and group A streptococci in patients with tonsillitis. Ann. Otol. Rhinol. Laryngol.106,571–574 (1997).
  Medline CASGoogle Scholar
• 60  Fujimori I, Yamada T: Incidence of α-streptococcus having inhibitory activity against β-streptococcus in patients with tonsillitis. Nippon Jibiinkoka Gakkai Kaiho95,400–408 (1992).
  Medline CASGoogle Scholar
• 61  Yamada T, Yokota Y, Ikeda F, Mine Y, Kitada T: Antibacterial activity of cefixime against Streptococcus pneumoniae, Streptococcus pyogenes, and Haemophilus influenzae in the presence of Moraxella (Branhamella) catarrhalis. Chemotherapy38,28–35 (1992).
  Medline CASGoogle Scholar
• 62  Brook I, Gober AE: Bacterial interference in the nasopharynx and nasal cavity of sinusitis prone and non-sinusitis prone children. Acta Otolaryngol.119,832–836 (1999).
  Medline CASGoogle Scholar
• 63  Roos K, Grahn E, Holm SE, Johansson H, Lind L: Interfering α-streptococci as a protection against recurrent streptococcal tonsillitis in children. Int. J. Pediatr. Otorhinolaryngol.25,141–148 (1993).
  Medline CASGoogle Scholar
• 64  Roos K, Hakansson EG, Holm S: Effect of recolonisation with “interfering” α streptococci on recurrences of acute and secretory otitis media in children: randomised placebo controlled trial. BMJ322,210–212 (2001).
  Medline CASGoogle Scholar
• 65  Roos K, Holm SE, Grahn E, Lind L: α-streptococci as supplementary treatment of recurrent streptococcal tonsillitis: a randomized placebo-controlled study. Scand. J. Infect. Dis.25,31–35 (1993).
  Medline CASGoogle Scholar
• 66  Falck G, Grahn-Hakansson E, Holm SE, Roos K, Lagergren L: Tolerance and efficacy of interfering α-streptococci in recurrence of streptococcal pharyngotonsillitis: a placebo-controlled study. Acta Otolaryngol.119,944–948 (1999).
  Medline CASGoogle Scholar
• 67  Dierksen KP, Inglis M, Tagg JR: High pharyngeal carriage rates of Streptococcus pyogenes in Dunedin school children with a low incidence of rheumatic fever. NZ Med. J.113,496–499 (2000).
  Medline CASGoogle Scholar
• 68  Fantinato V, Jorge AOC, Shimizu MT: Production of bacteriocin-like inhibitory substances (BLIS) by Streptococcus salivarius strains isolated from the tongue and throat of children with and without sore throat. Revista de Microbiologia30,332–334 (1999).
  CASGoogle Scholar
• 69  Tano K, Grahn-Hakansson E, Holm SE, Hellstrom S: Inhibition of OM pathogens by α-hemolytic streptococci from healthy children, children with SOM and children with rAOM. Int. J. Pediatr. Otorhinolaryngol.56,185–190 (2000).
  Medline CASGoogle Scholar
• 70  Walls T, Power D, Tagg J: Bacteriocin-like inhibitory substance (BLIS) production by the normal flora of the nasopharynx: potential to protect against otitis media? J. Med. Microbiol.52,829–833 (2003).
  Medline CASGoogle Scholar
• 71  Tanzer JM, Kurasz AB, Clive J: Inhibition of ecological emergence of mutans streptococci naturally transmitted between rats and consequent caries inhibition by Streptococcus salivarius TOVE-R infection. Infect. Immun.49,76–83 (1985).
  Medline CASGoogle Scholar
• 72  Tanzer JM, Kurasz AB, Clive J: Competitive displacement of mutans streptococci and inhibition of tooth decay by Streptococcus salivarius TOVE-R. Infect. Immun.48,44–50 (1985).▪ Describes targeted interference of mutans streptococci by the introduction of Streptococcus salivarius. Note that this study was carried out in a rat model.
  Medline CASGoogle Scholar
• 73  Tanzer JM, Kurasz AB, Clive J: Inhibiton of ecological emergence of mutans streptococci naturally transmitted between rats and consequent caries inhibition by Streptococcus salivarius TOVE-R infection. Infect. Immun.49,76–83 (1985).
  Medline CASGoogle Scholar
• 74  Kurasz AB, Tanzer JM, Bazer L, Savoldi E: In vitro studies of growth and competition between S. salivarius TOVE-R and mutans streptococci. J. Dent. Res.65,1149–1153 (1986).
  Medline CASGoogle Scholar
• 75  Sliepen I, Hofkens J, Van Essche M, Quirynen M, Teughels W: Aggregatibacter actinomycetemcomitans adhesion inhibited in a flow cell. Oral Microbiol. Immunol.23,520–524 (2008).
  Medline CASGoogle Scholar
• 76  Van Hoogmoed CG, Geertsema-Doornbusch GI, Teughels W, Quirynen M, Busscher HJ, Van der Mei HC: Reduction of periodontal pathogens adhesion by antagonistic strains. Oral Microbiol. Immunol.23,43–48 (2008).
  Medline CASGoogle Scholar
• 77  Teughels W, Newman MG, Coucke W et al.: Guiding periodontal pocket recolonization: a proof of concept. J. Dent. Res.86,1078–1082 (2007).
  Medline CASGoogle Scholar
• 78  Kazor CE, Mitchell PM, Lee AM et al.: Diversity of bacterial populations on the tongue dorsa of patients with halitosis and healthy patients. J. Clin. Microbiol.41,558–563 (2003).
  Medline CASGoogle Scholar
• 79  Burton J, Chilcott C, Tagg J: The rationale and potential for the reduction of oral malodour using Streptococcus salivarius probiotics. Oral Dis.11,29–31 (2005).
  MedlineGoogle Scholar
• 80  Burton JP, Chilcott CN, Moore CJ, Speiser G, Tagg JR: A preliminary study of the effect of probiotic Streptococcus salivarius K12 on oral malodour parameters. J. Appl. Microbiol.100,754–764 (2006).▪▪ Demonstrates a direct effect of the application of S. salivarius K12 on oral malodor, which is the first description of a measurable outcome from the use of a streptococcal probiotic.
  Medline CASGoogle Scholar
• 81  Tong H, Chen W, Merritt J, Qi F, Shi W, Dong X: Streptococcus oligofermentans inhibits Streptococcus mutans through conversion of lactic acid into inhibitory H₂O₂: a possible counteroffensive strategy for interspecies competition. Mol. Microbiol.63,872–880 (2007).
  Medline CASGoogle Scholar
• 82  Balakrishnan M, Simmonds RS, Tagg JR: Diverse activity spectra of bacteriocin-like inhibitory substances having activity against mutans streptococci. Caries Res.35,75–80 (2001).
  Medline CASGoogle Scholar
• 83  van der Hoeven JS, Schaeken MJ: Streptococci and actinomyces inhibit regrowth of Streptococcus mutans on gnotobiotic rat molar teeth after chlorhexidine varnish treatment. Caries Res.29,159–162 (1995).
  Medline CASGoogle Scholar
• 84  van der Hoeven JS, van den Kieboom CW, Schaeken MJ: Sulfate-reducing bacteria in the periodontal pocket. Oral Microbiol. Immunol.10,288–290 (1995).
  Medline CASGoogle Scholar
• 85  Kang MS, Chung J, Kim SM, Yang KH, Oh JS: Effect of Weissella cibaria isolates on the formation of Streptococcus mutans biofilm. Caries Res.40,418–425 (2006).
  MedlineGoogle Scholar
• 86  Kumar PS, Leys EJ, Bryk JM, Martinez FJ, Moeschberger ML, Griffen AL: Changes in periodontal health status are associated with bacterial community shifts as assessed by quantitative 16S cloning and sequencing. J. Clin. Microbiol.44,3665–3673 (2006).
  Medline CASGoogle Scholar
• 87  Favier CF, Vaughan EE, De Vos WM, Akkermans AD: Molecular monitoring of succession of bacterial communities in human neonates. Appl. Environ. Microbiol.68,219–226 (2002).
  Medline CASGoogle Scholar
• 88  Park HK, Shim SS, Kim SY et al.: Molecular analysis of colonized bacteria in a human newborn infant gut. J. Microbiol.43,345–353 (2005).
  Medline CASGoogle Scholar
• 89  Carlsson J, Grahnen H, Jonsson G, Wikner S: Early establishment of Streptococcus salivarius in the mouths of infants. J. Dent. Res.49,415–418 (1970).
  Medline CASGoogle Scholar
• 90  Frandsen EV, Pedrazzoli V, Kilian M: Ecology of viridans streptococci in the oral cavity and pharynx. Oral Microbiol. Immunol.6,129–133 (1991).
  Medline CASGoogle Scholar
• 91  Liljemark WF, Gibbons RJ: Suppression of Candida albicans by human oral streptococci in gnotobiotic mice. Infect. Immun.8,846–849 (1973).
  Medline CASGoogle Scholar
• 92  MacFarlane TW: The oral ecology of patients with severe Sjogren’s syndrome. Microbios41,99–106 (1984).
  Medline CASGoogle Scholar
• 93  Dierksen KP, Ragland NL, Tagg JR: A new alkaline pH-adjusted medium enhances detection of β-hemolytic streptococci by minimizing bacterial interference due to Streptococcus salivarius. J. Clin. Microbiol.38,643–650 (2000).
  Medline CASGoogle Scholar
• 94  Dierksen KP, Tagg JR: The influence of indigenous bacteriocin producing Streptococcus salivarius on the acquisition of Streptococcus pyogenes by primary school children in Dunedin, New Zealand. In: Streptococci and Streptococcal Diseases: Entering the New Millenium. Martin DR, Tagg JR (Eds). Securacopy, Wellington, New Zealand, 81–85 (2000).
  Google Scholar
• 95  Heikkila MP, Saris PE: Inhibition of Staphylococcus aureus by the commensal bacteria of human milk. J. Appl. Microbiol.95,471–478 (2003).
  Medline CASGoogle Scholar
• 96  Martin R, Langa S, Reviriego C et al.: The commensal microflora of human milk: new perspectives for food bacteriotherapy and probiotics. Trends Food Sci. Technol.15,121–127 (2004).
  CASGoogle Scholar
• 97  Dalidowitz C: Fortified breast milk safety. J. Am. Diet. Assoc.105,1572–1573 (2005).
  MedlineGoogle Scholar
• 98  Martin R, Heilig HG, Zoetendal EG et al.: Cultivation-independent assessment of the bacterial diversity of breast milk among healthy women. Res. Microbiol.158,31–37 (2007).
  MedlineGoogle Scholar
• 99  Abdelgadir WS, Hamad SH, Møller PL, Jakobsen M: Characterisation of the dominant microbiota of Sudanese fermented milk Rob. Int. Dairy J.11,63–70 (2001).
  Google Scholar
• 100  Mogensen G, Salminen S, O’Brien J et al.: Health benefits and safety evaluation of certain food components. Food microorganisms – health benefits, safety evaluation and strains with documented history of use in foods. Int. Dairy Fed. (IDF)4–20 (2002).
  Google Scholar
• 101  Abdelgadir WS, Hamad SH, Møller PL, Jakobsen M: Diversity of lactic acid bacteria isolated from AOC Salers cheese. J. Dairy Res.71,231–244 (2004).
  MedlineGoogle Scholar
• 102  Kurwijila L: Technologies for enhancing value addition, quality and safety of milk produced by smallholder farmers in Africa. Proceedings of the 4th All Africa Conference on Animal Agriculture (AACAA) and 31st Annual Meeting of Tanzania Society for Animal Production (TSAP). Arusha, Tanzania, 20–24 September 2005.
  Google Scholar
• 103  Pesic-Mikulec D: Microbiological study of fresh white cheese. Appl. Ecol. Environ. Res.4,129–134 (2005).
  Google Scholar
• 104  Obodai M, Dodd CE: Characterization of dominant microbiota of a Ghanaian fermented milk product, nyarmie, by culture- and nonculture-based methods. J. Appl. Microbiol.100,1355–1363 (2006).
  Medline CASGoogle Scholar
• 105  Van Hoorde K, Verstraete T, Vandamme P, Huys G: Diversity of lactic acid bacteria in two Flemish artisan raw milk Gouda-type cheeses. Food Microbiol.25,929–935 (2008).
  Medline CASGoogle Scholar
• 106  Jaine R, Baker M, Venugopal K: Epidemiology of acute rheumatic fever in New Zealand 1996–2005. J. Paediatr. Child Health44,564–571 (2008).
  MedlineGoogle Scholar
• 107  North DA, Heynes RA, Lennon DR, Neutze J: Analysis of costs of acute rheumatic fever and rheumatic heart disease in Auckland. NZ Med. J.106,400–403 (1993).
  Medline CASGoogle Scholar
• 108  Burton JP, Wescombe PA, Tagg JR, Chilcott CN: Safety assessment of the oral cavity probiotic Streptococcus salivarius K12. Appl. Environ. Microbiol.72,3050–3053 (2006).
  Medline CASGoogle Scholar
• 109  Maragkoudakis PA, Papadelli M, Georgalaki M et al.: In vitro and in vivo safety evaluation of the bacteriocin producer Streptococcus macedonicus ACA-DC 198. Int. J. Food Microbiol.133,141–147 (2009).
  Medline CASGoogle Scholar
• 110  Qi F, Chen P, Caufield PW: Purification of mutacin III from group III Streptococcus mutans UA787 and genetic analyses of mutacin III biosynthesis genes. Appl. Environ. Microbiol.65,3880–3887 (1999).
  Medline CASGoogle Scholar
• 111  Wirawan RE, Klesse NA, Jack RW, Tagg JR: Molecular and genetic characterization of a novel nisin variant produced by Streptococcus uberis. Appl. Environ. Microbiol.72,1148–1156 (2006).
  Medline CASGoogle Scholar
• 112  Mantovani HC, Russell JB: Bovicin HC5, a lantibiotic produced by Streptococcus bovis HC5, catalyzes the efflux of intracellular potassium but not ATP. Antimicrob. Agents Chemother.52,2247–2249 (2008).
  Medline CASGoogle Scholar
• 113  Mota-Meira M, Morency H, Lavoie MC: In vivo activity of mutacin B-Ny266. J. Antimicrob. Chemother.56,869–871 (2005).
  Medline CASGoogle Scholar
• 114  Hillman JD, Novak J, Sagura E et al.: Genetic and biochemical analysis of mutacin 1140, a lantibiotic from Streptococcus mutans. Infect. Immun.66,2743–2749 (1998).
  Medline CASGoogle Scholar
• 115  Qi F, Chen P, Caufield PW: Purification and biochemical characterization of mutacin I from the group I strain of Streptococcus mutans, CH43, and genetic analysis of mutacin I biosynthesis genes. Appl. Environ. Microbiol.66,3221–3229 (2000).
  Medline CASGoogle Scholar
• 116  Ross KF, Ronson CW, Tagg JR: Isolation and characterization of the lantibiotic salivaricin A and its structural gene salA from Streptococcus salivarius 20P3. Appl. Environ. Microbiol.59,2014–2021 (1993).▪ First characterization of a lantibiotic produced by S. salivarius.
  Medline CASGoogle Scholar
• 117  Jack RW, Tagg JR: Isolation and partial structure of streptococcin A-FF22. In: Nisin and Novel Lantibiotics. Jung G, Sahl H-G (Eds). Escom Publishers, Leiden, The Netherlands, 171–179 (1991).
  Google Scholar
• 118  Robson CL, Wescombe PA, Klesse NA, Tagg JR: Isolation and partial characterization of the Streptococcus mutans type AII lantibiotic mutacin K8. Microbiology153,1631–1641 (2007).
  Medline CASGoogle Scholar
• 119  Chikindas ML, Novak J, Driessen AJ, Konings WN, Schilling KM, Caufield PW: Mutacin II, a bactericidal lantibiotic from Streptococcus mutans. Antimicrob. Agents Chemother.39,2656–2660 (1995).
  Medline CASGoogle Scholar
• 120  Xiao H, Chen X, Chen M, Tang S, Zhao X, Huan L: Bovicin HJ50, a novel lantibiotic produced by Streptococcus bovis HJ50. Microbiology150,103–108 (2004).
  Medline CASGoogle Scholar
• 121  Yonezawa H, Kuramitsu HK: Genetic analysis of a unique bacteriocin, Smb, produced by Streptococcus mutans GS5. Antimicrob. Agents Chemother.49,541–548 (2005).
  Medline CASGoogle Scholar
• 122  Hyink O, Balakrishnan M, Tagg JR: Streptococcus rattus strain BHT produces both a class I two-component lantibiotic and a class II bacteriocin. FEMS Microbiol. Lett.252(2),235–241 (2005).
  Medline CASGoogle Scholar
• 201  WHO/73 PR: Attacking the attacker: WHO steps up its fight against rheumatic fever. (1999). www.who.int/inf-pr-1999/en/pr99-73.html
  Google Scholar